MOMENTUM 2026
Accelerating Europe´s action on cancer.
Accelerating Europe´s action on cancer.
Marking 75 years of advancing cancer research and care, The Swedish Cancer Society is convening Momentum. An international conference on accelerating cancer research into patient care.
About the conference
Momentum is an in-person conference bringing together policymakers, researchers, healthcare leaders, patient representatives, industry, investors and civil society to explore how to better coordinate efforts across sectors and borders to speed up progress — from research and regulation to data use and uptake of innovation.
The aim is to support more effective, sustainable and equitable cancer care in Europe.
Dates and format
- 14–16 October 2026
- Artipelag, Stockholm, Sweden
- In-person conference
Further details, including programme and ticket purchase, will be shared in March 2026.
"After 75 years of advancing cancer research, The Swedish Cancer Society is proud to convene Momentum. We know that scientific breakthroughs only matter when they reach patients — and that this requires strong collaboration across research, policy, healthcare and innovation. Momentum is created as a platform where these worlds come together, to turn knowledge into faster, fairer and more sustainable cancer care for people across Europe."
— Ulrika Årehed Kågström, Secretary General, The Swedish Cancer Society, and President, UICC
About the venue
Artipelag is located in the beautiful Stockholm archipelago, approximately 30 minutes from central Stockholm.
The venue offers a calm, natural setting for dialogue and collaboration.
Visit Artipelag for more information about the venue
Endorsed by
Contact
For inquiries, please contact:
About The Swedish Cancer Society
The Swedish Cancer Society is an independent, non-profit organisation working to beat cancer by funding research, spreading knowledge and influencing decision-makers.
We are one of the largest funders of cancer research in Sweden.
Our work depends on gifts and donations from individuals and companies.
Each year, we contribute 1 billion Swedish kronor to leading cancer research.
